Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci

The combination of the Totient technology with AbSci's platform provides the framework and data to enable in silico targeted drug design, and ultimately achieve the goals of making the best medicines available to patients in need. ...

Full "IntellAsia: Resources" article